ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Treatment outcomes in p16-negative oropharyngeal squamous cell carcinoma (OPSCC): A real-world retrospective data from a low-middle income countries (LMIC).
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiterature on contemporary outcomes of p16-negative OPSCC in India are limited, with existing evidence suggesting poorer prognosis compared to HPV-positive disease. MATERIALS AND
methodsWe conducted a retrospective study of patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC) who were treated with definitive intensity-modulated radiotherapy (IMRT) to a total dose of 66-70 Gy in 33 fractions over 6.5 weeks. The majority of patients received concurrent chemotherapy while a smaller proportion were treated with radiotherapy alone.
resultsThis retrospective study evaluated treatment outcomes in 181 patients with p16-negative (OPSCC) treated with definitive chemoradiotherapy or Radiation therapy (RT) alone between 2017 and 2024. All patients received intensity-modulated radiotherapy (IMRT) to 66-70 Gy in 33 fractions with 79% receiving concurrent chemotherapy, primarily weekly cisplatin. Median follow-up was 25 months. Locoregional recurrence occurred in 21.5% of patients while distant metastases developed in 26%. The 3 year overall survival and distant metastasis-free survival rates were 65% and 73%, respectively.
conclusionDespite adherence to protocol-based therapy, treatment failures especially distant relapses-remain common, underscoring the aggressive nature of p16-negative disease. Acute toxicities were comparable to available literature but manageable. These findings highlight the need for novel systemic strategies and biomarker-driven treatment intensification in this high-risk subgroup, particularly in resource-limited settings where the burden of p16-negative OPSCC remains high.
Indexed as
Identifiers
41276665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.